Skip to main content

Table 1 Baseline characteristics

From: Data-driven identification of endophenotypes of Alzheimer’s disease progression: implications for clinical trials and therapeutic interventions

 

Entire cohort

Class 1

Class 2

Class 3

Number of participants

1160

119

888

153

Duration of follow-up (months)

12.8 ± 5.9

13.6 ± 4.2

13.3 ± 5.7

9.1 ± 6.7

Age

75.6 ± 8.1

73.1 ± 8.9

76.1 ± 7.8

74.7 ± 8.6

Gender

 Female

590 (50.9)

58 (48.7)

443 (49.9)

89 (58.2)

 Male

472 (40.7)

50 (42.0)

367 (41.3)

55 (35.9)

 Missing

98 (8.4)

11 (9.2)

78 (8.8)

9 (5.9)

Education

14.0 ± 3.2

14.8 ± 3.2

13.9 ± 3.3

14.0 ± 2.9

Race

 Asian

8 (0.7)

1 (0.8)

6 (0.7)

1 (0.7)

 African American

59 (5.1)

6 (5)

45 (5.1)

8 (5.2)

 White

1007 (86.8)

103 (86.8)

771 (86.8)

133 (86.9)

 Other

28 (2.4)

0 (0)

22 (2.5)

6 (3.9)

 Missing

58 (5)

9 (7.6)

44 (5)

5 (3.3)

Marital status

 Divorced

70 (6.0)

8 (6.7)

55 (6.2)

7 (4.6)

 Married

800 (69.0)

90 (75.6)

603 (67.9)

107 (69.9)

 Never married

26 (2.2)

3 (2.5)

22 (2.5)

1 (0.7)

 Widowed

243 (20.9)

16 (13.4)

195 (22.0)

32 (20.9)

 Missing

21 (1.8)

2 (1.7)

13 (1.5)

6 (3.9)

ApoE4 carriers (%)a

63.5

65.7

63.6

62.6

Statin users

311 (26.8)

23 (19.3)

254 (28.4)

34 (22.2)

Baseline ADAS-cog

23.6 ± 9.6

26.5 ± 6.9

20.4 ± 6.7

40.9 ± 6.3

  1. Baseline characteristics of participants in the entire cohort and in each of the resulting latent classes (in the three-class model). Data presented as mean ± standard deviation or n (%) unless stated otherwise
  2. ADAS-cog Alzheimer’s Disease Assessment Scale—cognitive subscale, ApoE4 Apolipoprotein E, allele 4
  3. aPercent of those participants with relevant information available